Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients

[1]  A. Ferro,et al.  Comparative Pharmacokinetics and Pharmacodynamics of Platelet Adenosine Diphosphate Receptor Antagonists and their Clinical Implications , 2012, Clinical Pharmacokinetics.

[2]  D. Foley,et al.  Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. , 2012, Journal of the American College of Cardiology.

[3]  M. Alessi,et al.  Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade. , 2012, Thrombosis research.

[4]  T. Miyata,et al.  Pharmacogenomics of clopidogrel: evidence and perspectives. , 2011, Thrombosis research.

[5]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[6]  S. Yusuf,et al.  Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial , 2010, The Lancet.

[7]  Deepak L. Bhatt,et al.  Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. , 2010, Journal of the American College of Cardiology.

[8]  M. Fromm,et al.  Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. , 2010, Journal of the American College of Cardiology.

[9]  V. Deneer,et al.  Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. , 2010, JAMA.

[10]  G. Montalescot,et al.  Slow response to clopidogrel predicts low response. , 2010, Journal of the American College of Cardiology.

[11]  M. Keltai,et al.  Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study , 2010, The Lancet.

[12]  R. Abbate,et al.  High Residual Platelet Reactivity After Clopidogrel Loading and Long-Term Clinical Outcome After Drug-Eluting Stenting for Unprotected Left Main Coronary Disease , 2009, Circulation.

[13]  E. Antman,et al.  Population Pharmacokinetic Analyses to Evaluate the Influence of Intrinsic and Extrinsic Factors on Exposure of Prasugrel Active Metabolite in TRITON‐TIMI 38 , 2009, Journal of clinical pharmacology.

[14]  A. Siegbahn,et al.  Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease , 2009, European heart journal.

[15]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[16]  A. Siegbahn,et al.  Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. , 2008, Journal of the American College of Cardiology.

[17]  N. Farid,et al.  Quantitative determination of clopidogrel active metabolite in human plasma by LC-MS/MS. , 2008, Journal of pharmaceutical and biomedical analysis.

[18]  L. Wallentin,et al.  Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease , 2008, Journal of Pharmacokinetics and Pharmacodynamics.

[19]  G. Patti,et al.  Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. , 2008, Journal of the American College of Cardiology.

[20]  B. Baker,et al.  The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. , 2008, Journal of the American College of Cardiology.

[21]  W. Wijns,et al.  Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris. , 2008, The American journal of cardiology.

[22]  Matthew J Price,et al.  Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.

[23]  K. Winters,et al.  The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration , 2008, Thrombosis and Haemostasis.

[24]  M. Gawaz,et al.  The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score , 2007, Journal of thrombosis and haemostasis : JTH.

[25]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[26]  K. Toth,et al.  Clopidogrel resistance: role of body mass and concomitant medications. , 2007, International journal of cardiology.

[27]  A. Kastrati,et al.  Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. , 2007, The American journal of cardiology.

[28]  C. Macaya,et al.  Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.

[29]  M. Young,et al.  Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.

[30]  K. Winters,et al.  Clopidogrel poor responders: An objective definition based on Bayesian classification , 2007, Platelets.

[31]  F. Neumann,et al.  Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.

[32]  C. Macaya,et al.  Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. , 2006, Journal of the American College of Cardiology.

[33]  C. Macaya,et al.  Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? , 2004, The Journal of invasive cardiology.

[34]  U. Walter,et al.  CORONARY ARTERY DISEASE Original Studies Resistance to Thienopyridines: Clinical Detection of Coronary Stent Thrombosis by Monitoring of Vasodilator-Stimulated Phosphoprotein Phosphorylation , 2003 .